摘要:
The present invention relates to compounds of formula (I), pharmaceutical compositions which contain them and methods for treating cancer using compounds of formula (I).
wherein R 1 and R 2 are independently: (a) hydrogen; (b) (C 1 -C 5 )alkyl, optionally substituted with one or more of hydroxy or fluoro; or (c) halogen; A is phenyl, pyridine, or pyrimidine, optionally substituted with 1 or 2 substituents that are independently (C 1 -C 5 )alkyl, (C 1 -C 5 )alkoxy, (C 1 -C 5 )haloalkyl, (C 1 -C 5 )haloalkoxy, or halogen; B is phenylene or naphthylene, optionally substituted with 1 to 4 substituents that are independently (C 1 -C 5 )alkyl, (C 1 -C 5 )alkoxy, (C 1 -C 5 )haloalkyl, (C 1 -C 5 )haloalkoxy, or halogen; L is a bridging group which is -O-, -S-, -CH 2 -. M is phenyl, pyridine or pyrimidine, optionally substituted.
摘要:
The present invention relates to compounds of formula (I), pharmaceutical compositions which contain them and methods for treating cancer using compounds of formula (I).
wherein R 1 and R 2 are independently: (a) hydrogen; (b) (C 1 -C 5 )alkyl, optionally substituted with one or more of hydroxy or fluoro; or (c) halogen; A is phenyl, pyridine, or pyrimidine, optionally substituted with 1 or 2 substituents that are independently (C 1 -C 5 )alkyl, (C 1 -C 5 )alkoxy, (C 1 -C 5 )haloalkyl, (C 1 -C 5 )haloalkoxy, or halogen; B is phenylene or naphthylene, optionally substituted with 1 to 4 substituents that are independently (C 1 -C 5 )alkyl, (C 1 -C 5 )alkoxy, (C 1 -C 5 )haloalkyl, (C 1 -C 5 )haloalkoxy, or halogen; L is a bridging group which is -O-, -S-, or -CH 2 - M is phenyl, pyridine or pyrimidine, optionally substituted.